Becker's Healthcare January 3, 2025
Of the hundreds of drugs that entered the U.S. market in 2024, GoodRx has named 19 of them as the most notable.
Note: The chronological list does not include December approvals.
1. Dupixent (dupilumab) for chronic obstructive pulmonary disease: The monoclonal antibody, already approved for eczema, asthma and long-term sinus congestion with nasal polyps, became the first biologic approved for COPD on Sept. 27.
2. Cobenfy (xanomeline / trospium chloride) for schizophrenia: Approved Sept. 26, the oral medication targets muscarinic receptors in the brain, differing from other schizophrenia drugs that affect dopamine and serotonin balance. Cobenfy is the first new type of schizophrenia medication approved in decades.
3. FluMist (influenza nasal vaccine): The annual flu vaccine is...
Today's Sponsors
Today's Sponsor